Wednesday, September 23, 2026

Jerash Holdings And 3 Other Stocks Have Very High Payout Ratio

ViaNews Editorial Team

January 26, 2021

Jerash Holdings And 3 Other Stocks Have Very High Payout Ratio

We have gathered information regarding stocks with the highest payout ratio up to now. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

When investigating a potential investment, the dividend payout ratio is a good statistic to know and anything around 60 percent is considered high.

1. Tsakos Energy Navigation Ltd

37.31% Payout Ratio

Tsakos Energy Navigation Limited provides seaborne crude oil and petroleum product transportation services worldwide.

As claimed by Morningstar, Inc., the next dividend payment is on Dec 14, 2020, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 2.82%.

Tsakos Energy Navigation Ltd's sales growth this year is anticipated to be 45.3% and a negative 10% for next year.

Year-on-year quarterly revenue growth grew by 9%, now sitting on 687.89M for the twelve trailing months.

Tsakos Energy Navigation Ltd's sales growth is 26.7% for the current ongoing quarter and negative 3% for the next. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.87%.

Volatility

Tsakos Energy Navigation Ltd's last day, last week, and last month's average volatility was a positive 0.45%, a negative 0.21%, and a positive 0.00%, respectively.

Tsakos Energy Navigation Ltd's last day, last week, and last month's high and low average amplitude percentage was 5.15%, 4.40%, and 4.80%, respectively.

Tsakos Energy Navigation Ltd's Stock Yearly Top and Bottom Value

Tsakos Energy Navigation Ltd's stock is valued at $8.88 at 19:23 EST, way below its 52-week high of $23.85 and way above its 52-week low of $7.06.

Tsakos Energy Navigation Ltd's Moving Average

Tsakos Energy Navigation Ltd's value is below its 50-day moving average of $8.92 and higher than its 200-day moving average of $8.58.

2. Jerash Holdings

47.62% Payout Ratio

Jerash Holdings (US), Inc., through its subsidiaries, manufactures and exports customized and ready-made sports and outerwear.

As claimed by Morningstar, Inc., the next dividend payment is on Nov 12, 2020, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 3.29%.

Jerash Holdings's sales growth this year is anticipated to be negative 8.7% and 10.9% for next year.

Year-on-year quarterly revenue growth declined by 11.5%, now sitting on 85.68M for the twelve trailing months.

Jerash Holdings's sales growth for the next quarter is 55.6%. The company's growth estimates for the present quarter and the next is negative 83.3% and 242.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.44%.

Volatility

Jerash Holdings's last day, last week, and last month's average volatility was a negative 2.53%, a negative 0.31%, and a positive 0.54%, respectively.

Jerash Holdings's last day, last week, and last month's high and low average amplitude percentage was 4.66%, 3.09%, and 3.40%, respectively.

Jerash Holdings's Stock Yearly Top and Bottom Value

Jerash Holdings's stock is valued at $5.92 at 19:23 EST, way below its 52-week high of $7.14 and way above its 52-week low of $3.60.

Jerash Holdings's Moving Average

Jerash Holdings's value is above its 50-day moving average of $5.58 and way higher than its 200-day moving average of $4.95.

3. Schnitzer Steel Industries, Inc.

122.95% Payout Ratio

Schnitzer Steel Industries, Inc. recycles ferrous and nonferrous scrap metals; and manufactures finished steel products worldwide.

As stated by Morningstar, Inc., the next dividend payment is on Jan 13, 2021, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 2.37%.

Schnitzer Steel Industries, Inc.'s sales growth this year is anticipated to be 42.9% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 1.8B for the twelve trailing months.

Schnitzer Steel Industries, Inc.'s sales growth is 35.9% for the ongoing ongoing quarter and 88.6% for the next. The company's growth estimates for the present quarter and the next is 145.2% and 1200%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.85%.

Volatility

Schnitzer Steel Industries, Inc.'s last day, last week, and last month's average volatility was a positive 1.64%, a negative 1.04%, and a positive 0.28%, respectively.

Schnitzer Steel Industries, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 5.48%, 4.56%, and 5.32%, respectively.

Schnitzer Steel Industries, Inc.'s Stock Yearly Top and Bottom Value

Schnitzer Steel Industries, Inc.'s stock is valued at $31.59 at 19:23 EST, way below its 52-week high of $42.19 and way higher than its 52-week low of $10.09.

Schnitzer Steel Industries, Inc.'s Moving Average

Schnitzer Steel Industries, Inc.'s worth is under its 50-day moving average of $31.96 and way above its 200-day moving average of $23.21.

4. Utah Medical Products, Inc.

35.22% Payout Ratio

Utah Medical Products, Inc. manufactures and distributes medical devices for the healthcare industry in the United States, Europe, and internationally.

As maintained by Morningstar, Inc., the next dividend payment is on Dec 13, 2020, the estimated forward annual dividend rate is 1.14 and the estimated forward annual dividend yield is 1.31%.

Utah Medical Products, Inc.'s sales growth this year is anticipated to be negative 0% and a negative 0% for next year.

Year-on-year quarterly revenue growth declined by 16.1%, now sitting on 42M for the twelve trailing months.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.15%.

Volatility

Utah Medical Products, Inc.'s last day, last week, and last month's average volatility was a positive 1.00%, a negative 0.45%, and a positive 0.10%, respectively.

Utah Medical Products, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.02%, 3.09%, and 2.56%, respectively.

Utah Medical Products, Inc.'s Stock Yearly Top and Bottom Value

Utah Medical Products, Inc.'s stock is valued at $87.23 at 19:23 EST, way under its 52-week high of $109.00 and way above its 52-week low of $75.33.

Utah Medical Products, Inc.'s Moving Average

Utah Medical Products, Inc.'s value is below its 50-day moving average of $87.74 and above its 200-day moving average of $84.36.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com